The overarching goal of our research is to develop a clear understanding of the molecules and pathways involved in the pathoetiology of brain disorders and to use this information to develop new therapeutic targets.
More specifically, we are focusing our research on the monoamine neurotransmitters dopamine, serotonin, and norepinephrine that all play a central role in modulating most brain activity. We are interested in understanding the regulation of monoaminergic neurotransmission at all levels from the molecular level where we study monoaminergic proteins to the systems level where we study behaviors modulated by monoamines.
At the protein level, we are exploring the monoamine transporters (MATs), including the serotonin transporter (SERT), the dopamine transporter (DAT), and the norepinephrine transporter (NET). DAT, NET, and SERT serve a pivotal role in limiting monoamine-mediated neurotransmission through the reuptake of their respective neurotransmitters, and they are targets of some of the most effective and powerful psychoactive substances including antidepressants and psychostimulants. We are employing structure/function studies, molecular modeling and, in silico virtual drug screens to study transporter function and pharmacology. This work will position us to better understand how MATs in novel ways can be targeted therapeutically to treat mental disorders that involve monoamine signaling, including depression, ADHD, schizophrenia, impulse control disorders, and drug and alcohol abuse.
At the systems level of monoaminergic behaviors, we are currently focused on understanding what role long-term molecular adaptations in monoaminergic neurons play in psychostimulant addiction. We are developing and employing state-of-the-art, viral-based genetic tools that are designed to only target and modulate intracellular signaling in specific types of brain cells such as dopaminergic neurons. We believe this work has the potential to lead to novel therapeutic avenues for treating psychostimulant addiction. We also believe this strategy is not limited to studies of drug addiction and our studies will eventually be expanded to understand how intracellular signaling in particular neuronal populations contribute to various disease states of the brain including psychiatric disorders and neurodegenerative diseases such as Parkinson's, Alzheimer's and Huntington's.
News and Announcements
June 23, 2021
Ole gave a talk with the title “Allosteric modulation of monoamine transporters as a therapeutic target for drug addiction” at Medical University of Vienna, Vienna, Austria
June 21, 2021
Drexel STAR student Samantha Ita joined the lab – welcome!
June 2, 2021
Shaili published a paper on sydnocarb as an allosteric modulator of DAT
June 2, 2021
Drexel Medical Student Summer Research Fellow Sreya Muchivolu joined the lab – welcome!
May 10, 2021
Ole gave a talk with the title “Allosteric modulation of monoamine transporters as a therapeutic target for drug addiction” at Case Western Reserve University School of Medicine, Department of Physiology and Biophysics
May 5, 2021
A paper co-authored by Stacia and Ole, together with Dr. España, was published in Neuropsychopharmacology.
March 9, 2021
Pharmacology and Physiology PhD student Clara Xu joined the lab – welcome!
January 19, 2021
Ole was together with Dr. España awarded a CURE grant.
October 12, 2020
A paper co-authored by Stacia and Ole, together with Dr. España, was published in Journal of Neuroscience.
See more News and Announcements
Back to Top